Skip to main content

Table 2 Cerivcogenital HPV prevalence by genotype group and relative risk by vaccination status

From: Trends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003–2012

  Unvaccinated Vaccinated Relative risk
Age Genotypes N % + S.E. N % + S.E. RR 95 % CI
  All 244 17.5 2.7 233 20.1 3.5 1.1 0.7–1.8
14–17 Group 1 244 12.4 2.7 233 11.2 2.9 0.9 0.5–1.8
  6, 11, 16, 18 244 4.5 1.7 233 1.0 0.5 0.2 0.1–0.8
  All 448 57.7 3.4 241 56.9 3.5 1.0 0.8–1.2
18–24 Group 1 448 38.8 3.5 241 30.9 3.5 0.8 0.6–1.1
  6, 11, 16, 18 448 16.6 2.5 241 2.5 0.7 0.2 0.1–0.3
  1. Prevalence is by all, oncogenic (Group 1 genotypes), and vaccine genotypes for women ages 14–17 and 18–24 in 2009–12. Here, %+ denotes the weighted cervicogenital HPV prevalence of the listed genotypes among the N people in the population. Bold relative risks intervals do not contain 1